Further, pharmacological inhibition of ACL activity suppressed RIPK3-mediated kidney fibrosis in the UUO model, which suggests that RIPK3 is involved in metabolic regulation and may present as a promising therapeutic target in human CKD [95]. Here, RIPK3 is linked to chronic kidney disease.